Last reviewed 2026-04-20 · How we verify

Perjeta

At a glance

Approved indications

• HER2-positive carcinoma of breast
• HER2-positive colon cancer
• HER2-positive rectal cancer

Common side effects

• Diarrhea
• Alopecia
• Neutropenia
• Nausea
• Fatigue
• Rash
• Peripheral neuropathy
• Upper respiratory tract infection
• Headache
• Paronychia
• Febrile neutropenia
• Leukopenia

Serious adverse events

• Left ventricular dysfunction
• Febrile neutropenia

Key clinical trials

• HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
• Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (PHASE2)
• A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®. (PHASE1)
• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Perjeta CI brief — competitive landscape report
• Perjeta updates RSS · CI watch RSS
• BioRay Pharmaceutical Co., Ltd. portfolio CI